WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Options
Query Language
Stem
Sort by:
List Length
Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2012122107) APPARATUS, SYSTEM, AND METHOD FOR CREATING BIOLOGICALLY PROTECTED/ENHANCED SPACES IN VIVO
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2012/122107 International Application No.: PCT/US2012/027740
Publication Date: 13.09.2012 International Filing Date: 05.03.2012
IPC:
A61K 38/30 (2006.01) ,A61K 38/18 (2006.01) ,A61K 38/17 (2006.01) ,A61P 3/10 (2006.01) ,A61P 3/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
22
Hormones
30
Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
18
Growth factors; Growth regulators
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3
Drugs for disorders of the metabolism
08
for glucose homeostasis
10
for hyperglycaemia, e.g. antidiabetics
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3
Drugs for disorders of the metabolism
Applicants: KNEZEVICH, Charles[US/US]; US
SILVETZ, Robert, D.[US/US]; US
Inventors: KNEZEVICH, Charles; US
SILVETZ, Robert, D.; US
Agent: PARKER, James, S.; Saliwanchik, Lloyd & Eisenschenk P.O. Box 142950 Gainesville, FL 32614-2950, US
Priority Data:
61/449,61204.03.2011US
Title (EN) APPARATUS, SYSTEM, AND METHOD FOR CREATING BIOLOGICALLY PROTECTED/ENHANCED SPACES IN VIVO
(FR) APPAREIL, SYSTÈME, ET PROCÉDÉ POUR CRÉER DES ESPACES BIOLOGIQUEMENT PROTÉGÉS/AMÉLIORÉS IN VIVO
Abstract:
(EN) The present invention creates a biologically protected or enhanced space in vivo in a mammal to allow the mammal's immune system and/or other biological processes to function properly in order to treat autoimmune diseases. In particular, the biologically protected/enhanced space allows biological processes to occur that can therapeutically treat Type I diabetes. The biologically enhanced/protected space can also be used to promote growth of specific cells such as insulin producing islet cells of the pancreas. Microfluidic devices can also be used to remove soluble TNF receptors and autoreactive T Cells in treating autoimmune diseases. Additionally, microfluidic devices can be used to remove blood glucose, soluble insulin receptors and insulin-like growth factor (IGF) from blood in the treatment of adult onset (Type II) diabetes.
(FR) La présente invention permet de créer un espace biologiquement protégé ou amélioré in vivo chez un mammifère pour permettre au système immunitaire et/ou à d'autres processus biologiques du mammifère de fonctionner correctement pour traiter des maladies auto-immunes. En particulier, l'espace biologiquement protégé/amélioré permet que des processus biologiques qui peuvent traiter thérapeutiquement le diabète de type I se produisent. L'espace biologiquement protégé/amélioré peut également être utilisé pour favoriser la croissance de cellules spécifiques telles que les cellules d'îlot productrices d'insuline du pancréas. Des dispositifs microfluidiques peuvent également être utilisés pour éliminer des récepteurs de TNF solubles et des lymphocytes T autoréactifs dans le traitement de maladies auto-immunes. De plus, des dispositifs microfluidiques peuvent être utilisés pour éliminer le glucose sanguin, les récepteurs d'insuline solubles et le facteur de croissance insulinomimétique (IGF) du sang dans le traitement du diabète de l'adulte (type II).
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)